Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial (vol 376, pg 705, 2010)

被引：0
|
作者：
Kwo, P. Y.
Lawitz, E. J.
McCone, J.
机构：
来源：
LANCET | 2010年 / 376卷 / 9748期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1224 / 1224
页数：1
相关论文
共 50 条
  • [1] Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Kwo, Paul Y.
    Lawitz, Eric J.
    McCone, Jonathan
    Schiff, Eugene R.
    Vierling, John M.
    Pound, David
    Davis, Mitchell N.
    Galati, Joseph S.
    Gordon, Stuart C.
    Ravendhran, Natarajan
    Rossaro, Lorenzo
    Anderson, Frank H.
    Jacobson, Ira M.
    Rubin, Raymond
    Koury, Kenneth
    Pedicone, Lisa D.
    Brass, Clifford A.
    Chaudhri, Eirum
    Albrecht, Janice K.
    LANCET, 2010, 376 (9742): : 705 - 716
  • [2] HCV SPRINT-1: BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN FOR TREATMENT OF GENOTYPE 1 CHRONIC HEPATITIS C IN PREVIOUSLY UNTREATED PATIENTS
    Kwo, Paul
    Lawitz, Eric J.
    McCone, Jonathan
    Schiff, Eugene R.
    Vierling, John M.
    Pound, David
    Davis, Mitchell
    Galati, Joseph S.
    Gordon, Stuart C.
    Ravendhran, Natarajan
    Rossaro, Lorenzo
    Anderson, Frank H.
    Jacobson, Ira M.
    Rubin, Raymond
    Koury, Kenneth
    Chaudhri, Eirum I.
    Albrecht, Janice K.
    HEPATOLOGY, 2008, 48 (04) : 1027A - 1027A
  • [3] Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
    Kowdley, Kris V.
    Lawitz, Eric
    Crespo, Israel
    Hassanein, Tarek
    Davis, Mitchell N.
    DeMicco, Michael
    Bernstein, David E.
    Afdhal, Nezam
    Vierling, John M.
    Gordon, Stuart C.
    Anderson, Jane K.
    Hyland, Robert H.
    Dvory-Sobol, Hadas
    An, Di
    Hindes, Robert G.
    Albanis, Efsevia
    Symonds, William T.
    Berrey, M. Michelle
    Nelson, David R.
    Jacobson, Ira M.
    LANCET, 2013, 381 (9883): : 2100 - 2107
  • [4] HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C
    Kwo, P.
    Lawitz, E.
    McCone, J.
    Schiff, E.
    Vierling, J.
    Pound, D.
    Davis, M.
    Galati, J.
    Gordon, S.
    Ravendhran, N.
    Rossaro, L.
    Anderson, F.
    Jacobson, I.
    Rubin, R.
    Koury, K.
    Brass, C.
    Chaudhri, E.
    Albrecht, J.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S4 - S4
  • [5] ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
    Bronowicki, J-P
    Pol, S.
    Thuluvath, P.
    Larrey, D.
    Martorell, C. T.
    Rustgi, V. K.
    Morris, D. W.
    Younes, Z.
    Fried, M. W.
    Bourliere, M.
    Hezode, C.
    Reddy, R.
    Massoud, O.
    Abrams, G. A.
    Ratziu, V.
    He, B.
    Eley, T.
    Ahmad, A.
    Thiry, A.
    Llamoso, C.
    Mendez, P.
    Hughes, E.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S431 - S432
  • [6] BOCEPREVIR (BOC) COMBINED WITH PEGINTERFERON ALFA-2B/RIBAVIRIN (P/R) FOR TREATMENT-NAiVE PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE (G) 1: SPRINT-2 FINAL RESULTS
    Poordad, Fred
    McCone, Jonathan
    Bacon, Bruce R.
    Bruno, Savino
    Manns, Michael P.
    Sulkowski, Mark S.
    Jacobson, Ira M.
    Reddy, K. Rajender
    Boparai, Navdeep
    Sniukiene, Vilma
    Brass, Clifford A.
    Albrecht, Janice K.
    Bronowicki, Jean-Pierre
    HEPATOLOGY, 2010, 52 (04) : 402A - 403A
  • [7] BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
    Bronowicki, J. -P.
    Pol, S.
    Thuluvath, P. J.
    Larrey, D.
    Martorell, C. T.
    Rustgi, V. K.
    Morris, D. W.
    Younes, Z.
    Fried, M. W.
    Bourliere, M.
    Hezode, C.
    Massoud, O.
    Abrams, G. A.
    Ratziu, V.
    Thiry, A.
    Llamoso, C.
    Hughes, E. A.
    Hindes, R. G.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S472 - S472
  • [8] Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study
    Norio Hayashi
    Makoto Nakamuta
    Tetsuo Takehara
    Hiromitsu Kumada
    Akiko Takase
    Anita Yee Mei Howe
    Steven W. Ludmerer
    Niloufar Mobashery
    Journal of Gastroenterology, 2016, 51 : 390 - 403
  • [9] Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study
    Hayashi, Norio
    Nakamuta, Makoto
    Takehara, Tetsuo
    Kumada, Hiromitsu
    Takase, Akiko
    Howe, Anita Yee Mei
    Ludmerer, Steven W.
    Mobashery, Niloufar
    JOURNAL OF GASTROENTEROLOGY, 2016, 51 (04) : 390 - 403
  • [10] EFFICACY AND SAFETY OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN TREATMENT NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1
    Sulkowski, Mark S.
    Zeuzem, Stefan
    Lawitz, Eric
    Grigorescu, Mircea
    Tice, Alan D.
    Rustgi, Vinod K.
    Rodriguez-Torres, Maribel
    Lurie, Yoav
    Cianciara, Janusz
    Bacon, Bruce R.
    Bain, Vincent G.
    Kryczka, Wieslaw
    Pulkstenis, Erik
    Subramanian, G. M.
    McHutchison, John G.
    HEPATOLOGY, 2009, 50 (04) : 333A - 333A
12345